ALFACELL CORP
10-Q, EX-27.1, 2000-06-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: ALFACELL CORP, 10-Q, 2000-06-14
Next: ALFACELL CORP, 10-Q, EX-99.1, 2000-06-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     This schedule  contains summary  financial  information  extracted from the
Alfacell  Corporation  Balance Sheet as of April 30, 2000 and the  Statements of
Operations  for the nine months  ended April 30,  2000 and is  qualified  in its
entirety by reference to such financial statements.
</LEGEND>

<S>                                            <C>
<PERIOD-TYPE>                                           9-MOS
<FISCAL-YEAR-END>                                 JUL-31-2000
<PERIOD-END>                                      APR-30-2000
<CASH>                                               $895,134
<SECURITIES>                                                0
<RECEIVABLES>                                               0
<ALLOWANCES>                                                0
<INVENTORY>                                                 0
<CURRENT-ASSETS>                                    1,060,987
<PP&E>                                              1,143,637
<DEPRECIATION>                                      1,016,057
<TOTAL-ASSETS>                                      1,188,567
<CURRENT-LIABILITIES>                                 989,881
<BONDS>                                                     0
                                       0
                                                 0
<COMMON>                                               18,421
<OTHER-SE>                                            180,265
<TOTAL-LIABILITY-AND-EQUITY>                        1,188,567
<SALES>                                                     0
<TOTAL-REVENUES>                                       39,206
<CGS>                                                       0
<TOTAL-COSTS>                                       2,210,607
<OTHER-EXPENSES>                                            0
<LOSS-PROVISION>                                            0
<INTEREST-EXPENSE>                                      2,600
<INCOME-PRETAX>                                    (2,174,001)
<INCOME-TAX>                                          755,854
<INCOME-CONTINUING>                                (1,418,147)
<DISCONTINUED>                                              0
<EXTRAORDINARY>                                             0
<CHANGES>                                                   0
<NET-INCOME>                                       (1,418,147)
<EPS-BASIC>                                             (0.08)
<EPS-DILUTED>                                           (0.08)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission